Equities research analysts forecast that Cerus Co. (NASDAQ:CERS) will report sales of $19.27 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Cerus’ earnings, with the lowest sales estimate coming in at $19.23 million and the highest estimate coming in at $19.30 million. Cerus reported sales of $16.53 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 16.6%. The firm is scheduled to announce its next earnings results on Tuesday, February 25th.
According to Zacks, analysts expect that Cerus will report full-year sales of $72.98 million for the current fiscal year, with estimates ranging from $72.96 million to $73.00 million. For the next financial year, analysts anticipate that the company will report sales of $87.40 million, with estimates ranging from $85.60 million to $89.20 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Cerus.
Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Cerus had a negative return on equity of 100.59% and a negative net margin of 100.38%. The company had revenue of $18.00 million during the quarter, compared to the consensus estimate of $17.69 million. During the same quarter last year, the firm posted ($0.11) EPS. The firm’s quarterly revenue was up 16.9% on a year-over-year basis.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Cerus from a “sell” rating to a “hold” rating in a research note on Monday, October 7th. BidaskClub lowered Cerus from a “sell” rating to a “strong sell” rating in a report on Friday, October 25th. ValuEngine cut Cerus from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Stifel Nicolaus assumed coverage on Cerus in a report on Tuesday, August 27th. They set a “buy” rating and a $7.00 target price on the stock. Finally, BTIG Research upgraded Cerus from a “neutral” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $7.50.
CERS stock traded down $0.02 during mid-day trading on Friday, hitting $4.18. 36,491 shares of the company were exchanged, compared to its average volume of 933,202. The firm has a fifty day simple moving average of $4.35 and a 200 day simple moving average of $4.96. The company has a market capitalization of $608.99 million, a PE ratio of -9.55 and a beta of 1.57. Cerus has a twelve month low of $3.95 and a twelve month high of $6.88. The company has a current ratio of 2.77, a quick ratio of 2.31 and a debt-to-equity ratio of 0.95.
In other Cerus news, SVP Carol Moore sold 30,000 shares of Cerus stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $5.33, for a total value of $159,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.26% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Aperio Group LLC bought a new position in shares of Cerus during the second quarter worth about $27,000. Meristem Family Wealth LLC acquired a new stake in shares of Cerus in the second quarter valued at approximately $56,000. Jefferies Group LLC bought a new stake in shares of Cerus during the second quarter valued at approximately $75,000. Jane Street Group LLC bought a new stake in shares of Cerus during the second quarter valued at approximately $93,000. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of Cerus by 1,108.9% during the second quarter. Cubist Systematic Strategies LLC now owns 20,551 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 18,851 shares during the last quarter. 75.02% of the stock is currently owned by hedge funds and other institutional investors.
Cerus Company Profile
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Further Reading: What is the outlook for the FAANG stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.